Table 3. Incidence of cGvHD in period... | American Society of Hematology

Table 3.

Incidence of cGvHD in period 1993-1996

Risk factor	cGvHD, row %
Risk factor	No	Limited	Extensive
All patients	52	25	23
Sex^3-150,^3-151
Male	48	25	27
Female	58	24	18
Age, y^3-150,^3-151
Younger than 20	68	21	11
20-40	51	25	24
Older than 40	50	25	25
Donor-recipient sex combination^3-150,^3-151
Donor (F) + recipient (M)	41	26	33
Other	56	24	20
Interval between diagnosis and transplantation
Shorter than 12 mo	52	23	25
12 mo or longer	52	26	22
aGvHD prevention^3-150,^3-151
T-cell depletion	51	28	21
Cyclo alone	52	20	28
Cyclo + mtx	55	25	20
Other	28	22	50
Source of stem cells^3-150,^3-151
BM	54	25	21
PB	36	24	40
aGvHD^3-150,^3-151
Grade 0	69	15	16
Grade I	46	36	18
Grade II	34	31	35
Grade III	40	18	42
Grade IV	75	5	20

Risk factor	cGvHD, row %
Risk factor	No	Limited	Extensive
All patients	52	25	23
Sex^3-150,^3-151
Male	48	25	27
Female	58	24	18
Age, y^3-150,^3-151
Younger than 20	68	21	11
20-40	51	25	24
Older than 40	50	25	25
Donor-recipient sex combination^3-150,^3-151
Donor (F) + recipient (M)	41	26	33
Other	56	24	20
Interval between diagnosis and transplantation
Shorter than 12 mo	52	23	25
12 mo or longer	52	26	22
aGvHD prevention^3-150,^3-151
T-cell depletion	51	28	21
Cyclo alone	52	20	28
Cyclo + mtx	55	25	20
Other	28	22	50
Source of stem cells^3-150,^3-151
BM	54	25	21
PB	36	24	40
aGvHD^3-150,^3-151
Grade 0	69	15	16
Grade I	46	36	18
Grade II	34	31	35
Grade III	40	18	42
Grade IV	75	5	20

Abbreviations are explained in Table 1.

F3-150

Indicates that the χ² test for the comparison of the incidence of cGvHD (yes versus no) has a P < .05.

F3-151

Indicates that the χ² test for a linear trend over the grades from no to extensive (severity) comparing the risk factor levels is significant at the .05 level.

View Large

This Feature Is Available To Subscribers Only